Related Experiment Video
Updated: May 8, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis
Long Zhang1, Fangfang Zhou, Amaya García de Vinuesa
1Department of Molecular Cell Biology, Cancer Genomics Centre Netherlands and Centre for Biomedical Genetics, Leiden University Medical Center, Postbus 9600, 2300 RC Leiden, The Netherlands; Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Abstract:
TGF-β signaling is a therapeutic target in advanced cancers. We identified tumor necrosis factor receptor-associated factor 4 (TRAF4) as a key component mediating pro-oncogenic TGF-β-induced SMAD and non-SMAD signaling. Upon TGF-β stimulation, TRAF4 is recruited to the active TGF-β receptor complex, where it antagonizes E3 ligase SMURF2 and facilitates the recruitment of deubiquitinase USP15 to the TGF-β type I receptor (TβRI). Both processes contribute to TβRI stabilization on the plasma membrane and thereby enhance TGF-β signaling. In addition, the TGF-β receptor-TRAF4 interaction triggers Lys 63-linked TRAF4 polyubiquitylation and subsequent activation of the TGF-β-activated kinase (TAK)1. TRAF4 is required for efficient TGF-β-induced migration, epithelial-to-mesenchymal transition, and breast cancer metastasis. Elevated TRAF4 expression correlated with increased levels of phosphorylated SMAD2 and phosphorylated TAK1 as well as poor prognosis among breast cancer patients. Our results demonstrate that TRAF4 can regulate the TGF-β pathway and is a key determinant in breast cancer pathogenesis.
Insights
Tumor necrosis factor receptor-associated factor 4 (TRAF4) promotes cancer by enhancing transforming growth factor beta (TGF-β) signaling. TRAF4 drives TGF-β-induced cell migration and metastasis, indicating its role in breast cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Transforming growth factor beta (TGF-β) signaling is a critical pathway implicated in advanced cancers.
- Targeting TGF-β signaling presents a therapeutic strategy for cancer treatment.
Purpose of the Study:
- To identify key mediators of pro-oncogenic TGF-β signaling.
- To investigate the role of tumor necrosis factor receptor-associated factor 4 (TRAF4) in TGF-β-induced oncogenic processes.
Main Methods:
- Investigated TRAF4's interaction with the TGF-β receptor complex.
- Assessed the impact of TRAF4 on E3 ligase SMURF2 and deubiquitinase USP15 recruitment.
- Analyzed TGF-β-activated kinase 1 (TAK1) activation and TRAF4 polyubiquitylation.
- Correlated TRAF4 expression with patient prognosis and signaling markers.
Main Results:
- TRAF4 antagonizes SMURF2 and recruits USP15 to the TGF-β type I receptor (TβRI), stabilizing it.
- TRAF4 interaction with TGF-β receptor triggers Lys 63-linked polyubiquitylation and TAK1 activation.
- TRAF4 is essential for TGF-β-induced migration, epithelial-to-mesenchymal transition, and metastasis.
- Elevated TRAF4 expression correlates with increased pSMAD2, pTAK1, and poor breast cancer prognosis.
Conclusions:
- TRAF4 is a crucial regulator of TGF-β signaling in cancer.
- TRAF4 enhances TGF-β-mediated oncogenic signaling, contributing to breast cancer pathogenesis and metastasis.
Related Concept Videos
TGF - β Signaling Pathway
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Intracellular Signaling Affects Focal Adhesions
Some...

